Scroll for more

About

 

Alex Driggs
General Counsel, Corporate Secretary

Mr. Driggs became our General Counsel and Corporate Secretary in September 2017. Prior to his appointment, Mr. Driggs served as our Acting General Counsel and Corporate Secretary since June 2017, and our Vice President of Legal Affairs, Deputy General Counsel and Assistant Corporate Secretary from September 2015 to June 2017. He joined Sucampo in May 2015 as Associate General Counsel.

Prior to joining Sucampo, Mr. Driggs was an independent legal consultant for domestic and international biotechnology clients; in this role, he supported a wide range of commercial, securities, strategic and intellectual property transactions. During 2012, following AMGEN’s acquisition of Micromet, Inc., Mr. Driggs served as Senior Counsel in AMGEN’s Licensing & Alliance Management Group, where he negotiated license and collaboration agreements. From 2009 until 2012, Mr. Driggs was the Associate General Counsel for Micromet, Inc., a public biotechnology company that developed blinatumomab and other innovative antibody products. Mr. Driggs began his legal career at Cooley LLP as an associate in the Life Sciences and Technology Transactions groups.

Mr. Driggs received his law degree from New York University School of Law and his undergraduate degree, in Philosophy, from Harvard University. He is a member of the Virginia State Bar.

 
Contact Us
 
Tel: +1-301-961-3400
 

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.